Scarica l'app Stockscreener
8.57
0.12%
-0.010
Dopo l'orario di chiusura:
8.57
Precedente Chiudi:
$8.58
Aprire:
$8.57
Volume 24 ore:
522.28K
Relative Volume:
0.64
Capitalizzazione di mercato:
$389.41M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-17.49
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
+0.35%
1M Prestazione:
+104.53%
6M Prestazione:
+72.78%
1 anno Prestazione:
-40.32%
Intervallo 1D:
$8.56
$8.58
Intervallo di 1 settimana:
$8.54
$8.58
Portata 52W:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Nome
Y Mabs Therapeutics Inc
Settore
Industria
Telefono
646-885-8505
Indirizzo
202 CARNEGIE CENTER, PRINCETON, NY
Confronta YMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.57 | 388.95M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Iniziato | Oppenheimer | Outperform |
| 2024-08-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Iniziato | Truist | Buy |
| 2023-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-04-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-27 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-10-31 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-03 | Ripresa | Guggenheim | Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-22 | Ripresa | JP Morgan | Overweight |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-05-01 | Iniziato | Janney | Buy |
| 2020-04-29 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Iniziato | Wedbush | Outperform |
| 2019-04-01 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-10-16 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Will Y mAbs Therapeutics Inc. stock go up soonStop Loss & Stock Portfolio Risk Control - Newser
Sector ETF performance correlation with Y mAbs Therapeutics Inc.Weekly Gains Summary & Risk Adjusted Swing Trade Ideas - Newser
Is Y mAbs Therapeutics Inc. trading at a discountJuly 2025 Movers & Fast Gaining Stock Strategy Reports - khodrobank.com
Tools to monitor Y mAbs Therapeutics Inc. recovery probabilityTrade Risk Assessment & Free Daily Entry Point Trade Alerts - Newser
Real time breakdown of Y mAbs Therapeutics Inc. stock performanceJuly 2025 Intraday Action & Long-Term Investment Growth Plans - Newser
Custom watchlist performance reports with Y mAbs Therapeutics Inc.July 2025 Levels & Safe Capital Investment Plans - Newser
How to escape a deep drawdown in Y mAbs Therapeutics Inc.Weekly Investment Summary & AI Optimized Trade Strategies - Newser
Does Y mAbs Therapeutics Inc. fit your quant trading modelJuly 2025 Setups & Safe Swing Trade Setup Alerts - Newser
Chart based exit strategy for Y mAbs Therapeutics Inc.Trade Risk Summary & Detailed Earnings Play Alerts - Newser
Aug Big Picture: Is Y mAbs Therapeutics Inc. impacted by rising ratesMarket Weekly Review & High Conviction Buy Zone Alerts - خودرو بانک
Can Y mAbs Therapeutics Inc. navigate macro headwindsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - khodrobank.com
What is the long term forecast for Y mAbs Therapeutics Inc. stockJuly 2025 Weekly Recap & Weekly Top Stock Performers List - خودرو بانک
Can volume confirm reversal in Y mAbs Therapeutics Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Is Y mAbs Therapeutics Inc. forming bullish engulfing patternsEarnings Overview Report & Growth Focused Stock Reports - khodrobank.com
Can Y mAbs Therapeutics Inc. stock double in the next yearQuarterly Earnings Summary & High Accuracy Swing Entry Alerts - khodrobank.com
Y mAbs Therapeutics Inc. stock retracement – recovery analysis2025 Market WrapUp & Verified Momentum Stock Watchlist - Newser
Y mAbs Therapeutics Inc. stock volume spike explainedPortfolio Value Report & AI Enhanced Trading Alerts - Newser
Is Y mAbs Therapeutics Inc. impacted by rising rates2025 Pullback Review & Verified Chart Pattern Trade Signals - khodrobank.com
How to use Fibonacci retracement on Y mAbs Therapeutics Inc.Rate Hike & Precise Swing Trade Entry Alerts - Newser
Is Y mAbs Therapeutics Inc. stock a hidden gem2025 Price Action Summary & Low Drawdown Momentum Ideas - khodrobank.com
Can Y mAbs Therapeutics Inc. stock outperform in a bear marketTrade Volume Report & Long Hold Capital Preservation Plans - khodrobank.com
Can Y mAbs Therapeutics Inc. continue delivering strong returns2025 Bull vs Bear & Low Volatility Stock Recommendations - khodrobank.com
Using R and stats models for Y mAbs Therapeutics Inc. forecastingWeekly Trend Recap & Reliable Price Breakout Signals - Newser
Can Y mAbs Therapeutics Inc. outperform in the next rallyRecession Risk & AI Powered Market Entry Ideas - khodrobank.com
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy? - sharewise.com
Chart based analysis of Y mAbs Therapeutics Inc. trends2025 Market Trends & Real-Time Buy Zone Alerts - Newser
What institutional flow reveals about Y mAbs Therapeutics Inc.Earnings Risk Report & Verified Swing Trading Watchlists - Newser
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? - MSN
Exit strategy if you’re trapped in Y mAbs Therapeutics Inc.Market Growth Summary & Scalable Portfolio Growth Methods - Newser
Detecting support and resistance levels for Y mAbs Therapeutics Inc.July 2025 Snapshot & Entry and Exit Point Strategies - Newser
Can Y mAbs Therapeutics Inc. Rally Enough to Break Even getLinesFromResByArray error: size == 0 - newsyoung.net
Y-mAbs Therapeutics Reports Mixed Financial Results with Profitability Improvements and Sales Decline in August 2025 - Markets Mojo
Will Y mAbs Therapeutics Inc. continue its uptrend2025 Earnings Impact & Fast Gaining Stock Reports - Newser
Y mAbs Therapeutics Inc. recovery potential after sell offPortfolio Profit Report & Safe Capital Growth Tips - Newser
Ranking Y mAbs Therapeutics Inc. among high performing stocks via toolsForecast Cut & Free Technical Pattern Based Buy Signals - Newser
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Y Mabs Therapeutics Inc Azioni (YMAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):